Global Alpha Glucosidase Inhibitors Market Report 2024: Growth Rate, Major Segments And Regions

Spread the love

The Alpha Glucosidase Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Alpha Glucosidase Inhibitors Market:

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

According to The Business Research Company’s Alpha Glucosidase Inhibitors Global Market Report 2024, The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased incidence of diabetes, growth in awareness of diabetes management, advancements in diabetes treatment strategies, preference for oral antidiabetic medications, clinical research and evidence-based medicine..

The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing emphasis on early intervention, rising geriatric population, global healthcare initiatives for diabetes control, integration into combination therapies.. Major trends in the forecast period include patient-centric approaches, focus on type 2 diabetes management, technological advancements in drug delivery, emerging markets and globalization, collaborations and partnerships..

Rising diabetes prevalence globally is expected to propel the growth of the alpha-glucosidase inhibitors market going forward. Diabetes is a long-term metabolic condition marked by high blood glucose (also known as blood sugar) levels, which can seriously harm the heart, blood vessels, eyes, kidneys, and nerves over time. Alpha-glucosidase inhibitors prevent carbohydrate absorption from the small intestine, which inhibits the rise in postprandial blood glucose concentrations and helps control diabetes. For instance, in November 2022, according to the International Diabetes Federation, a Belgium-based organization for diabetes, globally, 537 million adults (or 1 in 10) had diabetes. Further, the global prevalence of diabetes is expected to increase by 643 million people by 2030 and 783 million people by 2045. Therefore, rising diabetes prevalence globally is driving the growth of the alpha-glucosidase inhibitors market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11880&type=smp

The alpha glucosidase inhibitors market covered in this report is segmented –

1) By Type: Dumping Syndrome, Type 2 Diabetes

2) By Drug class: Acarbose, Miglitol, Voglibose

3) By Constituent: Glucoamylase, Isomaltase, Maltase, Sucrase

4) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

Product innovation is a key trend gaining popularity in the alpha-glucosidase inhibitors market. Major companies operating in the alpha-glucosidase inhibitors market are developing innovative products to sustain their position in the market. For instance, in January 2023, TheracosBio, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin) to treat adults with type 2 diabetes. Brenzavvy is a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2). It is suggested as a supplement to diet and exercise to help people with type 2 diabetes better regulate their blood sugar levels by inducing the kidneys to excrete sugar through urine.

The alpha glucosidase inhibitors market report table of contents includes: